News Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:19 2024-12-13 EST			5-day change	1st Jan Change
87.74 ^CHF	-0.36%		-2.30%	+3.38%

12-12	Unsupported price hikes added $815 million to US drug spending in 2023	RE
12-11	Monte Rosa Closes Global License Agreement With Novartis	MT

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Unsupported price hikes added $815 million to US drug spending in 2023	12-12	RE
Monte Rosa Closes Global License Agreement With Novartis	12-11	MT
Swiss Equities Extend Losses; KOF Global Economic Barometers Stable	12-10	MT
Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment	12-10	MT
Novartis' Breast Cancer Combo Drug Lowers Distant Recurrence Risk in Late-stage Trial	12-10	MT
Novartis: Kisqali effective over the long term, according to data	12-10	CF
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer	12-10	GL
Longer-term Novartis Kisqali(R) NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer	12-10	DJ
Novartis Inc. Announces Results from an Updated Analysis of the Pivotal Phase III Natalee Trial of Kisqali®?	12-10	CI
NOVARTIS AG : Deutsche Bank remains Neutral	12-10	ZD
NOVARTIS AG : Jefferies remains Neutral	12-10	ZD
Novartis AG - Special Call	12-09
Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML	12-09	AQ
New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy	12-09	AQ
Novartis: positive long-term data in leukemia	12-09	CF
Novartis Logs Superior Efficacy Results in Longer-term Data for Leukemia Treatment	12-08	MT
Novartis Announces Positive, Long-Term Results from the Pivotal Phase III ASC4FIRST Trial with Scemblix	12-08	CI
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML	12-08	GL
Swiss Market Index Ends Week Little Changed; Holcim Shares Down	12-06	MT
Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy	12-06	MT
Novartis: positive data for Fabhalta in HPN	12-06	CF
Novartis' Rare Blood Disorder Drug Improves Hemoglobin Levels in Phase 3b Trial	12-06	MT
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy	12-06	GL
New Phase IIIB data shows Novartis Fabhalta(R) improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy	12-06	DJ
Novartis Announces Positive Topline Results from APPULSE-PNH, a Phase IIIB Study Evaluating the Efficacy and Safety of Two-Daily Oral Monotherapy Fabhalta	12-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

NOVARTIS : Q3 beat and a guidance upgrade; today’s dip is a buying opportunity

October 29, 2024 at 02:16 pm

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am